City

Atlanta (1)

Houston (1)

Johns Creek (1)

Condition

CCND1 Positive (2)

Mantle Cell Lymphoma (2)

CCND2 Positive (1)

CCND3 Positive (1)

CD20 Positive (1)

Recurrent Mantle Cell Lymphoma (1)

Refractory Mantle Cell Lymphoma (1)

t(11;14) Positive (1)

Overall Status

Active, not recruiting (2)

Sign in for free

Phase

phase 2 (2)

Sponsor

Emory University (1)

M.D. Anderson Cancer Center (1)

Collaborator

Genentech, Inc. (1)

National Cancer Institute (NCI) (1)

Intervention

bendamustine (1)

ibrutinib (1)

laboratory biomarker analysis (1)

obinutuzumab (1)

rituximab (1)

venetoclax (1)

Study Documents

Intervention Type

biological (2)

drug (2)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

ccnd1 positive

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)

Active, not recruiting

CCND1 Positive
+2 more

Bendamustine
+2 more

Atlanta, Georgia
+2 more

Nov 2, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting

CCND1 Positive
+6 more

Ibrutinib
+2 more

Houston, Texas

M D Anderson Cancer Center

Jan 11, 2022